Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021
Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year end of 2021.
Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.
Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.
The research report titled “Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021” examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilpesy Drugs Market.
The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market
Key Topics Covered in the Report
1. Vimpat(Lacosamide)
2. Keppra(Levetiracetam)
3. Briviact(Brivaracetam)
4. Lamictal(Lamotrigine)
5. Neurontin (Gabapentin)
6. Depakine (Sodium Valproate)
7. Sabril (Vigabatrin)
8. Onfi(Clobazam)
9. Fycompa(Perampanel)
10. Inovelon/Banzel(Rufinamide)
11. Zonegran (Zonisamide)
12. Zebinix (Eslicarbazepine Acetate)
Key Companies Covered in the Report are as follows:
1. UCB
2. EISAI
3. Pfizer
4. Sanofi
5. Lundbeck
Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.
Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.
The research report titled “Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021” examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilpesy Drugs Market.
The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market
Key Topics Covered in the Report
- Worldwide Epilepsy Drugs Market Analysis (2013 – 2021)
- Worldwide Epilepsy Drugs Market Share (2013 – 2021)
- Worldwide Epilepsy Drugs Brand Market Performance (2013 – 2021)
- Epilepsy Drugs Market – Major Deal Types
- Key Companies Analysis
- Key Drivers and Inhibitors of the Epilepsy Drugs Market
1. Vimpat(Lacosamide)
2. Keppra(Levetiracetam)
3. Briviact(Brivaracetam)
4. Lamictal(Lamotrigine)
5. Neurontin (Gabapentin)
6. Depakine (Sodium Valproate)
7. Sabril (Vigabatrin)
8. Onfi(Clobazam)
9. Fycompa(Perampanel)
10. Inovelon/Banzel(Rufinamide)
11. Zonegran (Zonisamide)
12. Zebinix (Eslicarbazepine Acetate)
Key Companies Covered in the Report are as follows:
1. UCB
2. EISAI
3. Pfizer
4. Sanofi
5. Lundbeck
1. EXECUTIVE SUMMARY
2. WORLDWIDE – EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2021)
3. WORLDWIDE – EPILEPSY DRUGS MARKET SHARE (2013 – 2021)
4. KEY DRIVERS AND INHIBITORS OF THE EPILEPSY DRUGS MARKET
4.1 Market Drivers
4.2 Inhibitors
5. WORLDWIDE – EPILEPSY DRUGS BRAND MARKET PERFORMANCE (2013 – 2021)
5.1 Vimpat(Lacosamide) – UCB
5.2 Keppra(Levetiracetam) – UCB
5.3 Briviact(Brivaracetam) – UCB
5.4 Lamictal(Lamotrigine) – GlaxoSmithKline
5.5 Neurontin (Gabapentin) – Pfizer
5.6 Depakine (Sodium Valproate) – Sanofi
5.7 Sabril (Vigabatrin) – Lundbeck
5.8 Onfi(Clobazam) – Lundbeck
5.9 Fycompa(Perampanel) – EISAI
5.10 Inovelon/Banzel(Rufinamide) – EISAI
5.11 Zonegran (Zonisamide) – EISAI
5.12 Zebinix (Eslicarbazepine Acetate) – EISAI
6. EPILEPSY DRUGS MARKET – MAJOR DEAL TYPES
6.1 Epilepsy Drugs Market – Collaboration Deals
6.2 Epilepsy Drugs Market – Licensing Agreement
6.3 Epilepsy Drugs Market – Partnerships Deals
7. KEY COMPANIES ANALYSIS
7.1 UCB
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.1 EISAI
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.2 Pfizer
7.2.1 Business Overview
7.2.2 Epilepsy Drugs – Latest Development & Trends
7.3 Sanofi
7.3.1 Business Overview
7.3.2 Epilepsy Drugs – Latest Development & Trends
7.4 Lundbeck
7.4.1 Business Overview
7.4.2 Epilepsy Drugs – Latest Development & Trends
2. WORLDWIDE – EPILEPSY DRUGS MARKET ANALYSIS (2013 – 2021)
3. WORLDWIDE – EPILEPSY DRUGS MARKET SHARE (2013 – 2021)
4. KEY DRIVERS AND INHIBITORS OF THE EPILEPSY DRUGS MARKET
4.1 Market Drivers
4.2 Inhibitors
5. WORLDWIDE – EPILEPSY DRUGS BRAND MARKET PERFORMANCE (2013 – 2021)
5.1 Vimpat(Lacosamide) – UCB
5.2 Keppra(Levetiracetam) – UCB
5.3 Briviact(Brivaracetam) – UCB
5.4 Lamictal(Lamotrigine) – GlaxoSmithKline
5.5 Neurontin (Gabapentin) – Pfizer
5.6 Depakine (Sodium Valproate) – Sanofi
5.7 Sabril (Vigabatrin) – Lundbeck
5.8 Onfi(Clobazam) – Lundbeck
5.9 Fycompa(Perampanel) – EISAI
5.10 Inovelon/Banzel(Rufinamide) – EISAI
5.11 Zonegran (Zonisamide) – EISAI
5.12 Zebinix (Eslicarbazepine Acetate) – EISAI
6. EPILEPSY DRUGS MARKET – MAJOR DEAL TYPES
6.1 Epilepsy Drugs Market – Collaboration Deals
6.2 Epilepsy Drugs Market – Licensing Agreement
6.3 Epilepsy Drugs Market – Partnerships Deals
7. KEY COMPANIES ANALYSIS
7.1 UCB
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.1 EISAI
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.2 Pfizer
7.2.1 Business Overview
7.2.2 Epilepsy Drugs – Latest Development & Trends
7.3 Sanofi
7.3.1 Business Overview
7.3.2 Epilepsy Drugs – Latest Development & Trends
7.4 Lundbeck
7.4.1 Business Overview
7.4.2 Epilepsy Drugs – Latest Development & Trends
LIST OF FIGURES
Figure 2–1: Worldwide – Epilepsy Drugs Market (Million US$),2013 – 2016
Figure 2–2: Worldwide – Forecast for Epilepsy Drugs Market (Million US$),2017 – 2021
Figure 5–1: Worldwide – Vimpat Drug Sales (Million US$), 2013 – 2016
Figure 5–2: Worldwide – Forecast for Vimpat Drug Sales (Million US$), 2017 – 2021
Figure 5–3: Worldwide – Keppra Drug Sales (Million US$), 2013 – 2016
Figure 5–4: Worldwide – Forecast for Keppra Drug Sales (Million US$), 2017 – 2021
Figure 5–5: Worldwide – Briviact Drug Sales (Million US$), 2016 – 2021
Figure 5–6: Worldwide – Lamictal Drug Sales (Million US$), 2013 – 2016
Figure 5–7: Worldwide – Forecast for Lamictal Drug Sales (Million US$), 2017 – 2021
Figure 5–8: Worldwide – Neurotin Drug Sales (Million US$), 2013 – 2016
Figure 5–9: Worldwide – Forecast for Neurotin Drug Sales (Million US$), 2017 – 2021
Figure 5–10: Worldwide – Depakine Drug Sales (Million US$), 2013 – 2016
Figure 5–11: Worldwide – Forecast for Depakine Drug Sales (Million US$), 2017 – 2021
Figure 5–12: Worldwide – Sabril Drug Sales (Million US$), 2013 – 2016
Figure 5–13: Worldwide – Forecast for Sabril Drug Sales (Million US$), 2017 – 2021
Figure 5–14: Worldwide – Onfi Drug Sales (Million US$), 2013 – 2016
Figure 5–15: Worldwide – Forecast for Onfi Drug Sales (Million US$), 2017 – 2021
Figure 5–16: Worldwide – Fycompa Drug Sales (Million US$), 2013 – 2016
Figure 5–17: Worldwide – Forecast for Fycompa Drug Sales (Million US$), 2017 – 2021
Figure 5–18: Worldwide – Inovelon/Banzel Drug Sales (Million US$), 2013 – 2016
Figure 5–19: Worldwide – Forecast for Inovelon/Banzel Drug Sales (Million US$), 2017 – 2021
Figure 5–20: Worldwide – Zonegran Drug Sales (Million US$), 2013 – 2016
Figure 5–21: Worldwide – Forecast for Zonegran Drug Sales (Million US$), 2017 – 2021
Figure 5–22: Worldwide – Zebinix Drug Sales (Million US$), 2013 – 2016
Figure 5–23: Worldwide – Forecast for Zebinix Drug Sales (Million US$), 2017 – 2021
Figure 2–1: Worldwide – Epilepsy Drugs Market (Million US$),2013 – 2016
Figure 2–2: Worldwide – Forecast for Epilepsy Drugs Market (Million US$),2017 – 2021
Figure 5–1: Worldwide – Vimpat Drug Sales (Million US$), 2013 – 2016
Figure 5–2: Worldwide – Forecast for Vimpat Drug Sales (Million US$), 2017 – 2021
Figure 5–3: Worldwide – Keppra Drug Sales (Million US$), 2013 – 2016
Figure 5–4: Worldwide – Forecast for Keppra Drug Sales (Million US$), 2017 – 2021
Figure 5–5: Worldwide – Briviact Drug Sales (Million US$), 2016 – 2021
Figure 5–6: Worldwide – Lamictal Drug Sales (Million US$), 2013 – 2016
Figure 5–7: Worldwide – Forecast for Lamictal Drug Sales (Million US$), 2017 – 2021
Figure 5–8: Worldwide – Neurotin Drug Sales (Million US$), 2013 – 2016
Figure 5–9: Worldwide – Forecast for Neurotin Drug Sales (Million US$), 2017 – 2021
Figure 5–10: Worldwide – Depakine Drug Sales (Million US$), 2013 – 2016
Figure 5–11: Worldwide – Forecast for Depakine Drug Sales (Million US$), 2017 – 2021
Figure 5–12: Worldwide – Sabril Drug Sales (Million US$), 2013 – 2016
Figure 5–13: Worldwide – Forecast for Sabril Drug Sales (Million US$), 2017 – 2021
Figure 5–14: Worldwide – Onfi Drug Sales (Million US$), 2013 – 2016
Figure 5–15: Worldwide – Forecast for Onfi Drug Sales (Million US$), 2017 – 2021
Figure 5–16: Worldwide – Fycompa Drug Sales (Million US$), 2013 – 2016
Figure 5–17: Worldwide – Forecast for Fycompa Drug Sales (Million US$), 2017 – 2021
Figure 5–18: Worldwide – Inovelon/Banzel Drug Sales (Million US$), 2013 – 2016
Figure 5–19: Worldwide – Forecast for Inovelon/Banzel Drug Sales (Million US$), 2017 – 2021
Figure 5–20: Worldwide – Zonegran Drug Sales (Million US$), 2013 – 2016
Figure 5–21: Worldwide – Forecast for Zonegran Drug Sales (Million US$), 2017 – 2021
Figure 5–22: Worldwide – Zebinix Drug Sales (Million US$), 2013 – 2016
Figure 5–23: Worldwide – Forecast for Zebinix Drug Sales (Million US$), 2017 – 2021
LIST OF TABLES
Table 3 1: Worldwide – Epilepsy Drugs Market Share(Percent),2013 – 2016
Table 3 2: Worldwide – Forecast for Epilepsy Drugs Market Share(Percent),2017 – 2021
Table 4 1: Epilepsy Branded Drugs Price List(US$),2017
Table 6 1: Collaboration Deals in Epilepsy Drug Market, 2008 – 2017
Table 6 2: Licensing Agreement in Epilepsy Drug Market, 2008 – 2016
Table 6 3: Partnerships Deals in Epilepsy Drug Market, 2008 – 2016
Table 3 1: Worldwide – Epilepsy Drugs Market Share(Percent),2013 – 2016
Table 3 2: Worldwide – Forecast for Epilepsy Drugs Market Share(Percent),2017 – 2021
Table 4 1: Epilepsy Branded Drugs Price List(US$),2017
Table 6 1: Collaboration Deals in Epilepsy Drug Market, 2008 – 2017
Table 6 2: Licensing Agreement in Epilepsy Drug Market, 2008 – 2016
Table 6 3: Partnerships Deals in Epilepsy Drug Market, 2008 – 2016
